Özkan E - Search Results

1

Negative Histopathological Prognostic Factors Affecting Morbidity in T1 Differentiated Thyroid Carcinoma.

Araz M, Özkan E, Gunduz P, Soydal C, Küçük NÖ, Kır KM. Araz M, et al. Among authors: ozkan e. Cancer Biother Radiopharm. 2022 Feb;37(1):56-62. doi: 10.1089/cbr.2020.4679. Epub 2021 Sep 15. Cancer Biother Radiopharm. 2022. PMID: 34524012

2

Colonic visualization during renal scintigraphy secondary to ureterosigmoidostomy.

Ozkan E, Ozlem N, Küçük K, Kir KM, Erbay G. Ozkan E, et al. Clin Nucl Med. 2001 May;26(5):477-8. doi: 10.1097/00003072-200105000-00031. Clin Nucl Med. 2001. PMID: 11317044 No abstract available.

3

Visualization of collaterals in budd-chiari syndrome with Tc-99m MDP bone scintigraphy and Tc-99m HMPAO-labeled leukocyte scintigraphy.

Küşük NO, Ozkan E, Aras G, Kir KM. Küşük NO, et al. Among authors: ozkan e. Clin Nucl Med. 2003 Mar;28(3):236-7. doi: 10.1097/01.RLU.0000053536.24594.B9. Clin Nucl Med. 2003. PMID: 12592138 No abstract available.

4

Uncommon extent involvement of sarcoidosis in 18F-FDG PET/CT.

Küçük NO, Ozkan E, Aras G. Küçük NO, et al. Among authors: ozkan e. Eur J Nucl Med Mol Imaging. 2007 Dec;34(12):2151. doi: 10.1007/s00259-007-0555-6. Epub 2007 Sep 14. Eur J Nucl Med Mol Imaging. 2007. PMID: 17874096 No abstract available.

5

Detection of thyroid plasmacytoma by F-18 FDG PET/CT imaging.

Ozkan E, Tokmak E, Kir KM. Ozkan E, et al. Clin Nucl Med. 2008 Apr;33(4):292-3. doi: 10.1097/RLU.0b013e3181662b56. Clin Nucl Med. 2008. PMID: 18356675

6

Efficacy of adding high-dose In-111 octreotide therapy during Sandostatin treatment in patients with disseminated neuroendocrine tumors: clinical results of 14 patients.

Ozkan E, Tokmak E, Kucuk NO. Ozkan E, et al. Ann Nucl Med. 2011 Jul;25(6):425-31. doi: 10.1007/s12149-011-0482-2. Epub 2011 Apr 8. Ann Nucl Med. 2011. PMID: 21476058

7

The role of 18F-FDG-PET/CT in the preoperative staging and posttherapy follow up of gastric cancer: comparison with spiral CT.

Ozkan E, Araz M, Soydal C, Kucuk ON. Ozkan E, et al. World J Surg Oncol. 2011 Jul 14;9:75. doi: 10.1186/1477-7819-9-75. World J Surg Oncol. 2011. PMID: 21752303 Free PMC article.

8

Selective intraarterial radionuclide therapy with Yttrium-90 (Y-90) microspheres for unresectable primary and metastatic liver tumors.

Kucuk ON, Soydal C, Lacin S, Ozkan E, Bilgic S. Kucuk ON, et al. Among authors: ozkan e. World J Surg Oncol. 2011 Aug 6;9:86. doi: 10.1186/1477-7819-9-86. World J Surg Oncol. 2011. PMID: 21819613 Free PMC article.

9

Impact of ¹⁸F-FDG PET/CT for detecting recurrence of medullary thyroid carcinoma.

Ozkan E, Soydal C, Kucuk ON, Ibis E, Erbay G. Ozkan E, et al. Nucl Med Commun. 2011 Dec;32(12):1162-8. doi: 10.1097/MNM.0b013e32834bbe09. Nucl Med Commun. 2011. PMID: 21946617

10

Intra-arterial treatment with 90yttrium microspheres in treatment-refractory and unresectable liver metastases of neuroendocrine tumors and the use of 111in-octreotide scintigraphy in the evaluation of treatment response.

Lacin S, Oz I, Ozkan E, Kucuk O, Bilgic S. Lacin S, et al. Among authors: ozkan e. Cancer Biother Radiopharm. 2011 Oct;26(5):631-7. doi: 10.1089/cbr.2011.0957. Epub 2011 Sep 27. Cancer Biother Radiopharm. 2011. PMID: 21950557 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

404 results

Search Page